Skip to content

Axsome Therapeutics AXSM Debt Repayments

Debt Repayments at other companies

Eli Lilly logo
Eli LillyLLY
$750M
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0-100%
Arrowhead Research logo
Arrowhead ResearchARWR
$17.83M-88.2%
Abbott logo
AbbottABT
$1.42B+41.5%

Other financials

Income statement

See full
Revenue$191.2M+57.4%
Gross profit$176.5M+58.0%
Operating income-$63.4M-11.2%
Net income-$64.5M-8.6%
EPS (diluted)-$1.26-3.3%

Balance sheet

See full
Cash & equivalents$305.1M+1.4%
Total debt$219.9M+4.1%
Total equity$54.6M+2.6%
Total assets$713.6M+19.6%

Cash flow

See full
Operating cash flow-$20.7M+52.3%
CapEx$121.0K-64.2%
Free cash flow-$20.8M+52.4%

Valuation

See full
Market cap$12.89B+52.0%
Enterprise value$12.81B+52.9%
P/S18.2×-1.4×

Profitability

See full
Gross margin92.6%+1.1pp
Operating margin-24.4%-9.3pp
Net margin-26.6%-9.8pp
FCF margin-10.2%-3.9pp

Returns & leverage

See full
Return on equity-349.4%+109pp
Debt / equity+0.1×
Current ratio1.4×-0.6×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebt.

The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axsome Therapeutics's debt repayments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Axsome Therapeutics's debt repayments?
Axsome Therapeutics (AXSM) reported debt repayments of $70M in Q1 2026.
What does debt repayments mean?
Cash used to pay down the principal amount of debt.
How do you interpret debt repayments?
An increase signals active debt reduction or the maturity of debt instruments, which reduces future interest burdens.
How does debt repayments compare across companies?
Varies significantly based on the company's capital structure and debt maturity schedule compared to industry peers.